Scope of report
- The report provides a snapshot of the global therapeutic landscape of Spinal muscular atrophy.
- The report assesses Spinal muscular atrophy pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Spinal muscular atrophy pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Spinal muscular atrophy ranging from discovery to pre-registration and undisclosed stages.
Lexicon Genetics, Neurotune, PTC Therapeutics, Navinta LLC, Academia Sinica, Genzyme Corporation, Genzyme Corporation, Isis Pharmaceuticals, Neurodyn, Novartis Pharmaceuticals Corporation, Cytokinetics, RaNA Therapeutics, Voyager Therapeutics, AveXis, Bioblast Pharma, Novartis, AndroScience Corporation
Olesoxime, Sodium phenylbutyrate liquid, Nusinersen, Sodium valproate, RG 3039, BVS 857, CK 2127107, RG 7800, AVXS 101, LMI 070, RG 7916, ASC JM.X1, STL 182, Sodium phenylbutyrate, Gabapentin, ASCJ 9, Tirasemtiv, Vamorolone, Trehalose,
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800